These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25194178)

  • 1. Mechanisms behind the link between obesity and gastrointestinal cancers.
    Tilg H; Moschen AR
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):599-610. PubMed ID: 25194178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
    Baranova A; Tran TP; Birerdinc A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immune activation in obesity.
    Lumeng CN
    Mol Aspects Med; 2013 Feb; 34(1):12-29. PubMed ID: 23068074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: steatosis, the metabolic syndrome and cancer.
    Bugianesi E
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():40-3. PubMed ID: 16225471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis.
    Wainwright P; Scorletti E; Byrne CD
    Curr Diab Rep; 2017 Apr; 17(4):20. PubMed ID: 28290049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAFLD, NASH and liver cancer.
    Michelotti GA; Machado MV; Diehl AM
    Nat Rev Gastroenterol Hepatol; 2013 Nov; 10(11):656-65. PubMed ID: 24080776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatocellular carcinoma: Increase in incidence or future plague?].
    Raoul JL; Raimbourg J; Hiret S; Adhoute X; Senellart H
    Bull Cancer; 2018 May; 105(5):502-507. PubMed ID: 29567280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.
    Dyson J; Jaques B; Chattopadyhay D; Lochan R; Graham J; Das D; Aslam T; Patanwala I; Gaggar S; Cole M; Sumpter K; Stewart S; Rose J; Hudson M; Manas D; Reeves HL
    J Hepatol; 2014 Jan; 60(1):110-7. PubMed ID: 23978719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer.
    Cani PD; Jordan BF
    Nat Rev Gastroenterol Hepatol; 2018 Nov; 15(11):671-682. PubMed ID: 29844585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and gastrointestinal cancer.
    Donohoe CL; Pidgeon GP; Lysaght J; Reynolds JV
    Br J Surg; 2010 May; 97(5):628-42. PubMed ID: 20306531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers.
    Sanna C; Rosso C; Marietti M; Bugianesi E
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity, type 2 diabetes and risk of digestive cancer.
    Hillon P; Guiu B; Vincent J; Petit JM
    Gastroenterol Clin Biol; 2010 Oct; 34(10):529-33. PubMed ID: 20864282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Mahli A; Hellerbrand C
    Dig Dis; 2016; 34 Suppl 1():32-9. PubMed ID: 27548267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease: an emerging pathological spectrum.
    Zafrani ES
    Virchows Arch; 2004 Jan; 444(1):3-12. PubMed ID: 14685853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19.
    Ji D; Zhang M; Qin E; Zhang L; Xu J; Wang Y; Cheng G; Wang F; Lau G
    Metabolism; 2021 Feb; 115():154437. PubMed ID: 33220249
    [No Abstract]   [Full Text] [Related]  

  • 19. [Liver disorders in diabetic patients].
    Brůha R; Dvořák K; Petrtýl J
    Vnitr Lek; 2013 Jul; 59(7):546-50. PubMed ID: 23909257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.